

**VICKI L. SCHNELL, M.D.**  
**Medical Director**  
**Center of Reproductive Medicine, P.A.**

1015 Medical Center Blvd., Suite 2100  
Webster, TX 77598

Phone: (281) 332-0073  
Fax: (281)724-2032

---

**EDUCATION**

Undergraduate      Rice University, Houston, TX  
1979                      B.A. in Biochemistry

Graduate              Baylor College of Medicine, Houston, TX  
1983                      Doctor of Medicine

**POSTGRADUTE TRAINING**

Internship &          Baylor College of Medicine, Houston, TX  
Residency              Obstetrics & Gynecology  
1983 – 1987

Fellowship              Wayne State University, Detroit, MI  
1987 - 1989              Reproductive Endocrinology & Infertility

**LICENSURE**

Texas, # G5581, June 1983  
Michigan, #50962, April 1987

**BOARD CERTIFICATION**

1990                      American Board of Obstetrics & Gynecology  
1992                      Reproductive Endocrinology & Infertility Subspecialty

**HONORS/AWARDS**

Phi Epsilon Chemistry Honor Society  
Brown Service Award, Rice University  
Dean's List, Six Semesters – Undergraduate Program  
Honors in Clinical Endocrinology, High Risk Obstetrics, Reproductive  
Endocrinology, Clinical Pathology & Radiology

**PROFESSIONAL MEMBERSHIPS**

American College of Obstetrics & Gynecology  
American Society of Reproductive Medicine  
Society of Assisted Reproductive Endocrinology  
American Institute of Ultrasound Medicine  
Harris County Medical Society  
American Medical Association  
Texas Medical Association

**CLINICAL/HOSPITAL AFFILIATIONS**

Associate Clinical Professor, University of Texas Medical Branch, Galveston, TX

Hospital and Surgery Care Center Privileges: Bay Area Surgicenter, Baptist Beaumont Surgical Affiliates - Beaumont, Clear Lake Regional Medical Center, Houston Physician Hospital, Southeast Memorial Hermann, Christus-St. John Hospital, St. Luke's Episcopal Hospital, TX Women's Hospital, University of Texas Medical Branch (UTMB) Hospital, and Christus-St. Elizabeth Hospital - Beaumont

### **TRAINING**

May 2011	Da Vinci Surgical System Off-Site Training Program
1994 – 2010	ASRM Annual Postgraduate Courses & Meetings
1993	The Clinical Role of FSH, Study Group
1992	American Fertility Society Postgraduate Course, Molecular Endocrinology for Clinicians
	Advanced Assisted Reproductive Technology Seminar
1991	Molecular Endocrinology
	Frontiers in Reproductive Endocrinology
1990	Periconceptual Molecular Biology & Growth Factors
	Advanced Pelviscopy Course
1989	Transforming Basic Science into Reproductive Medicine
1988	Novel Substances in Reproduction
	Microsurgery Course – 40 hours

### **PUBLICATIONS**

1. Poindexter A.N. III, Schnell, V.L.: Abortion seeking behavior among low income women: Comparison of public surveys and group behavior. Public Health, London 96:328-333, 1982.
2. Schnell, V.L., Ataya K., Moore, R., Sacco A.: Bupivacaine is less toxic than Lidocaine and Chloroprocaine in the mouse in vitro fertilization system, Reprod Toxicol 6:323-327, 1992.
3. Schnell V.L., Yandell, R.B., Van Zandt S., Dinh T.V.: Enterobius vermicularis salpingitis: Distant episode form precipitating appendicitis, Obstet Gynecol 80:553-555, 1992.
4. Schnell, V.L., Nagamani M., Yallampalli C.: Insulin-like growth factor I binding is elevated in GnRH against treated uterine leiomyoma. Am J Obstet Gynecol, accepted with revisions.

### **PUBLISHED ABSTRACTS**

1. Schnell V.L., Poindexter, A.N. III, Battaglia, C.J.: A practical measurement of free testosterone: The predicted free testosterone index. District VII. The American College of Obstetrics and Gynecology, September 19, 1984.
2. Schnell V.L., Martens, M., Phillips, L.E., Faro, S.: The predictive role of intraoperative cultures on the incidence of post-caesarean section endometriosis. Annual McLaughlin Fellowship Colloquium, 1987.
3. Schnell, V.L., Ataya, K., Sacco, A., Moore, R.: Lidocaine decreases mouse in vitro fertilization and embryo cleavage. 44<sup>th</sup> Annual Meeting, American Fertility Society, 1988.

4. Ataya, K., Pydyn, E., Schnell, V.L., Sacco, A.: "Activated" cyclophosphamide inhibits mouse oocyte in vitro fertilization (IVF) and cleavage. 44<sup>th</sup> Annual Meeting, American Fertility Society, 1988.
5. Schnell V.L., Ataya, K., Sacco, A., Ellis, M.: Midaolam at Physiological levels does not adversely affect mouse in vitro fertilization and embryo cleavage. 45<sup>th</sup> Annual Meeting, American Fertility Society, 1989.
6. Schnell V.L., Smith, E.R., Armstrong S., Nagamani, M.: Serum concentration of CA 125 and CA 72 in patients with ovarian hyper stimulation syndrome. The Endocrine Society, 72<sup>nd</sup> Annual Meeting, June 20-23, 1990.
7. Schnell, V.L., Ataya, K., Sacco, A., Moore, R.: The comparative effect of Lidocaine, Bupivacaine and Chloroprocaine on cleavage and embryo development. American Fertility Society, 46<sup>th</sup> Annual Meeting, October 13-18, 1990.
8. Schnell, V.L., Blacker, C.M., Moghissi, K.S., Kroeger, M.: Ovulation prediction by salivary and vaginal electrical resistance monitoring in a diverse infertility population. 38<sup>th</sup> Annual Clinical Meeting. American Fertility Society, 46<sup>th</sup> Annual Meeting, October 13-18-, 1990.
9. Schnell, V.L., Nagamani, M., Yallampalli, C.: Effect of gonadotropin releasing hormone against treatment on insulin-like growth factor binding in myomas. Society for Gynecologic Investigation, 38<sup>th</sup> annual meeting, March 23, 1991.
10. Broady, B., Schnell, V.L., Kelly, B., Nagamani, M.: The clinical benefits of preoperative GnRH - a treatment of large uterine leiomyomata. ACOG District VII Annual Meeting, November 11, 1991, Puerto Vallarta, Mexico.
11. Schnell, V.L., Vanoye, C., Nagamani, M.: Carbon dioxide laser versus microelectrocautery for the treatment of distal tubal obstruction in the rabbit model: Peritoneal Adhesion scoring. Eight Annual Scientific Session of the Academy of Surgical Research, Chicago, IL September 19-22, 1992.
12. Nichtberger, T.D., Viancos, T.L., Federick, S.K., Peterman, K.A., Schnell, V.L.: Chlamydia IgG and IgM serology screening associated with poor pregnancy prognosis in an In-Vitro Fertilization Program. American Society of Reproductive Medicine, Annual Meeting, 1992, Toronto, CA, Nurses Profession Group Prize Presentation Award.
13. Viancos, T.L., Nichtberger, T.D., Fusillo, M., Frederick, S.K., Schnell, V.L.: Endometrial Thickness and Endometrial Patterns as Predictors of First Trimester Spontaneous Abortion (SpAb) in Pregnancies Achieved Through Intra-Uterine Insemination (IUI), American Society of Reproductive Medicine, Annual Meeting, San Diego, CA, 2000.
14. Richards, J., Stegner, T., Schnell, V.L. : Blastocyst Transfers on Day 5 with and without Assisted Hatching on Day 3, American Society of Reproductive Medicine, Annual Meeting, San Diego, CA, 2000.

### **CLINICAL RESEARCHES/STUDIES**

- **UTMB Small Grants Program**

Carbon dioxide laser versus micro-electro surgery for the treatment of distal tubal obstruction in the rabbit model: A macroscopic, histologic, and physiologic evaluation of the peritoneum and plasminogen activator changes - April 1990

- **3M Pharmaceuticals/Biopharm Clinical Services, Inc.**

- Multicenter study comparing the efficacy and safety of a once-a-week estradiol transdermal drug delivery patch to placebo

- Multicenter study comparing the efficacy and safety of a once-a-week estradiol transdermal patch to Premarin  
December 1990 – September 1991

- **Syntex Research**

Ninety days of treatment with intranasal nafarelin acetate (Synarel) plus iron vs. iron alone to improve anemia before surgical management of uterine leiomyomata  
December 1990

- **UTMB William and Mary Grant**

Ovarian Hyper stimulation Syndrome and CA 125 - July 1991

- **ICI Pharmaceuticals, Inc.**

A multicenter placebo controlled trial of 3.6mg Zoladex therapy for fibroids – May 1992

- **ICI Pharmaceuticals, Inc.**

A multi-center trial comparing 3.6mg Zoladex therapy with and without hormone replacement therapy for the treatment of endometriosis – October 1992

- **Abbott Laboratories**

Lupron Depot 3.75mg vs Lo/Ovral in the management of endometriosis – September 1992

- **Abbott Laboratories/PRN**

Combination Lupron Depot – Hormonal Add-Back in the management of Endometriosis  
September 1993

- **Ferring**

A randomized, comparative, 3 arm, parallel group, open-label study of the efficacy and safety of purified human FSH (hFSH) SC and Repronex SC when combined continuous or sequential dose ratios in female patients 19-33 years of age, undergoing In-Vitro Fertilization (IVF) – January 2001

- **EMD Serono, Inc.**

A phase III, prospective, randomized, assessor blind, multi-center, multi-national, comparative trial of a new formulation of r-hFSH versus Fertinex and Gonel-F in oligoanovulatory infertile women undergoing ovulation induction – March 2001

- **Tap Pharmaceuticals**

A Phase III, 12-month, randomized, double-blinded study to evaluate the efficacy and safety (including Bone-Density Assessment) of two doses of J867 versus Placebo in Subjects with Uterine Leiomyomata – July 2002

- **Ferring**

A randomized quality of life, efficacy, safety and tolerability (QUEST) study of Bravelle + Repronex vs. Gonel-F in controlled ovarian hyper stimulation for In Vitro Fertilization (IVF) – June 2003

- **Tap Pharmaceuticals**

A Phase 3, 12 month, extension study to evaluate the safety of Asoprisnil in subjects with

- **Barrier Therapeutics**  
 A multi-center, randomized double blind, comparative, safety and efficacy study of a single dose of 400mg Itraconazole given as two 200mg film-coated tablets versus a single dose of 150 Fluconazole given as a single tablet in
- **Wyeth**  
 A double blind randomized, placebo-controlled dose-ranging study of the effects ERB-041 in the reduction of symptoms associated with endometriosis in reproductive aged women – October 2004
- **Upsher-Smith Pharmaceuticals**  
 Placebo-controlled, randomized, double-blind, multi-center study to demonstrate the efficacy of 12 weeks of treatment with USL-221 on moderate to severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in postmenopausal women – January 2005
- **EMD Serono, Inc.**  
 A phase II, prospective, randomized, double-blind, placebo-controlled, multi center, dose finding, comparative study for the evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) versus Clomiphene Citrate in stimulating follicular Growth and Ovulation in infertile women with ovulatory disorder – February 2005
- **Ferring**  
 A multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three dosage strengths of Pulsatile GnRH administered intravenously or subcutaneously (via Portable Infusion Pump) compared to oral treatment with Clomiphene Citrate in anovulatory or oligoovulatory infertile females – March 2005
- **Ferring**  
 A multi-center, randomized, open-label, parallel group study of a vaginal micronized Progesterone tablet (Endometrin) compared to Crinone 8% vaginal gel in female patients undergoing In Vitro Fertilization (IVF) – August 2005
- **Xanodyne Pharmaceuticals**  
 A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate efficacy and safety of 0.65 g and 1.3 g oral dose of Xp 12B – MR TID administration during menstruation for the treatment of Menorrhagia – January 2007
- **EMD Serono, Inc.**  
 A phase IV, multi-center, randomized, double-blind, clinical trial to confirm the efficacy of the 75 IU dose of Luveris® Vs. Placebo when administered with Follitropin Alpha for induction of follicular development and pregnancy in Hypogonadotropic Hypogonadal women with profound LH deficiency, as defined by a baseline LH level of <1.2 IU/L – 2007
- **Neurocrine Biosciences, Inc.**  
 A phase II, randomized, double-blind, active-controlled study to assess the safety and efficacy of NBI-56418 in subjects with endometriosis – 2007

- **EMD Serono, Inc.**  
 A phase II, multicenter, randomized, assessor-blinded, active-comparator, dose-finding study to evaluate AS900672-enriched versus Follitropin Alfa (Gonel-F®) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology - 2007
- **Xanodyne Pharmaceuticals**  
 A multi-center, open label extension study to evaluate the safety of a 1.3 G oral dose of XP12B-MR TID administered during menstruation for the treatment of Menorrhagia - 2007
- **Duramed Research, Inc.**  
 A phase III, single-blind, randomized study to compare DR-2011 to a Progesterone Vaginal Gel for luteal phase supplementation for In-Vitro Fertilization – 2008
- **Ferring**  
 Protocol 2008-03 (GnRH Patch) - A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered from an Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment with Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females – December 2008
- **Repros**  
 A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women with Symptomatic Uterine Fibroids" Protocol Number ZPU-304 - March 2009
- **Repros**  
 A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women with Symptomatic Uterine Fibroids Requiring Hysterectomy", Protocol Number ZPU-301 – March 2009
- **Schering-Plough**  
 A Phase III, randomized, double-blind, active-controlled, non-inferiority trial to investigate the efficacy and safety of a single injection of SCH 900962 (corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (recFSH) as a reference in women aged 35 to 42 years (Phase 3; Protocol No. P06029) – 2010
- **Schering-Plough**  
 Follow-up protocol to collect the outcome and safety of frozen-thawed embryo transfer (FTET) cycles after cryopreservation of embryos in clinical study P06029 (Phase 3; Protocol No. 06031) - 2010

- **Agile Pharmaceuticals**  
 ATI-CL12: An open-label, randomized, parallel group, Phase III study of the contraceptive efficacy and safety of Agile transdermal contraceptive delivery system (TCDS) in comparison to a low-dose oral contraceptive containing 0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel in a 21-day regimen – 2010
- **EMD Serono, Inc.**  
 Exploratory, non-interventional study to identify and validate biomarkers in follicular fluid, cumulus or granulosa cells or embryo culture media for prediction of implantation and pregnancy outcome of Assisted Reproductive Technology cycle 2010
- **Warner Chilcott**  
 PR-00110 - Effect of WC3043 on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled, Parallel-group Study – 2011
- **Ferring**  
 FE999906 CS12 – Menopur Mixed Protocol: A non-inferiority study comparing fertilization rate between the combination of Menopur and Bravelle mixed in the same syringe and Menopur alone, both administered subcutaneously, in subjects undergoing ART – 2011
- **Warner Chilcott**  
 A randomized, double-blind, vehicle-controlled study of the safety and efficacy of WC3011 Estradiol Vaginal Gel in the treatment of symptoms of vulvovaginal atrophy in postmenopausal women - 2011